Radiance Biopharma to Participate in 2025 BIO CEO & Investor Conference
Management will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.
About Radiance Biopharma
Radiance is a biotechnology company developing next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer. RB-164, is a ‘Best in Class’, anti-ROR-1 ADC, for the treatment of liquid and solid tumors. RB-201, is a ‘First in Class’ anti- HER2/TROP2 Bispecific ADC, utilizing next generation tandem linker-payload technology, for the treatment of solid tumors.
Contacts For more information, please visit www.radiancebiopharma.com Contact us at Info@radiancebiopharma.com Office Tel. 617.621.7143
Robert Brooks
Radiance Biopharma
email us here
Visit us on social media:
LinkedIn
Distribution channels: Banking, Finance & Investment Industry, Companies, Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry, Science
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release
